Bitget App
Trading lebih cerdas
Beli kriptoPasarTradingFuturesEarnWawasanSelengkapnya
Harga
Data
Tentang
ROIV stock price forecast
Kompetitor
Tokenisasi
Kripto
FAQ
Logo saham Roivant Sciences Ltd.

Roivant Sciences Ltd.

ROIV·NASDAQ

Terakhir diperbarui pada 2026-02-11 07:49 EST. Informasi harga saham bersumber dari TradingView dan merefleksikan harga pasar real time.

Insight
Kalkulator
Berita

Perubahan harga saham ROIV

Pada hari perdagangan terakhir, saham ROIV ditutup pada harga 27.82 USD, dengan perubahan harga sebesar 0.56% untuk hari tersebut.
Perdagangan futures saham

Tentang Bitget

Exchange Universal (UEX) pertama di dunia, yang memungkinkan pengguna untuk trading tidak hanya mata uang kripto, tetapi juga saham, ETF, forex, emas, dan aset dunia nyata (RWA).
Pelajari selengkapnya

Data utama ROIV

Penutupan sebelumnya27.82 USD
Kap. pasar19.91B USD
Volume2.27M
Rasio P/E-
Imbal hasil deviden (12 Bulan Terakhir)0.00%
Jumlah dividen-
Tanggal tanpa dividen terakhir-
Tanggal pembayaran terakhir-
EPS terdilusi (12 Bulan Terakhir)-1.17 USD
Pendapatan bersih (Tahun Fiskal)−171.98M USD
Pendapatan (Tahun Fiskal)29.05M USD
Tanggal laporan berikutnyaJul 1, 2026
Estimasi EPS-0.300 USD
Estimasi pendapatan-
Saham beredar437.45M
Beta (1T)0.74
Tokenized stocks

Apakah kamu pernah mendengar tentang saham yang ditokenisasi?

Cara baru untuk trading saham — kapan saja, di mana saja, 24/7.

Pelajari selengkapnya

Ringkasan Roivant Sciences Ltd.

Roivant Sciences Ltd. bergerak di bidang biofarmasi yang berfokus pada pengembangan obat-obatan yang bersifat transformasional. Portofolio produknya meliputi Vtama, Batoclimab, Brepocitinib, Namilumab, dan RVT-2001, yang ditujukan untuk mengobati psoriasis, dermatitis atopik, penyakit mata tiroid, dan penyakit lainnya. Perusahaan ini didirikan oleh Vivek Ramaswamy pada 7 April 2014 dan berkedudukan di London, Inggris Raya.
Sektor
Teknologi kesehatan
Industri
Farmasi: Perusahaan Besar
CEO
Matthew Gline
Kantor Pusat
London
Situs web
roivant.com
Didirikan
2021
Karyawan (Tahun Fiskal)
750
Perubahan (1T)
−158 −17.40%
Pendapatan / Karyawan (1T)
38.74K USD
Pendapatan bersih / karyawan (1T)
−726.68K USD

ROIV Pulse

Daily updates on ROIV stock prices, fund flows, and market news, generated by AI and reviewed by our team of analysts. Always DYOR.

• Perubahan harga saham ROIV 24 jam: +7,16%. Dari 25,82 USD menjadi 27,67 USD. Lonjakan ini terutama didorong oleh data klinis positif fase 2 untuk brepocitinib pada sarkoidosis kutan dan penyelesaian pendaftaran pasien fase 2 untuk mosliciguat, yang menutupi kerugian keuangan Q3 yang lebih besar dari perkiraan.
• Dari perspektif teknis, ROIV berada dalam fase "breakout bullish kuat" setelah menembus resistance utama di $21,97. Meskipun RSI sebesar 82,8 menunjukkan kondisi overbought dalam jangka pendek, saham tetap jauh di atas rata-rata pergerakan 50 hari ($22,22) dan 200 hari ($17,97), menandakan momentum naik yang kuat didukung oleh volume perdagangan tinggi.
• Roivant Sciences mengumumkan hasil positif uji klinis fase 2 untuk obat brepocitinib pada sarkoidosis kutan, menunjukkan tingkat respons pasien 100% pada kelompok dosis tinggi, sehingga direncanakan studi fase 3 pada tahun 2026.
• Pulmovant, anak perusahaan Roivant, menyelesaikan pendaftaran pasien untuk uji klinis PHocus fase 2 mosliciguat untuk penyakit paru lebih cepat dari jadwal, dengan data utama diharapkan pada paruh kedua tahun 2026.
• Roivant melaporkan hasil keuangan Q3 2026 dengan kerugian bersih sebesar $265,9 juta dari pendapatan $2 juta, meskipun analis tetap fokus pada cadangan kas $4,5 miliar dan potensi pipeline tahap akhir.
• Eli Lilly menandatangani kesepakatan senilai $2,4 miliar untuk mengakuisisi Orna Therapeutics, spesialis RNA sirkular dan terapi CAR-T, menandai akuisisi bioteknologi besar kedua dalam dua hari seiring meningkatnya aktivitas M&A di sektor tersebut.
• FDA mengeluarkan Permintaan Informasi untuk meningkatkan pengungkapan gluten dalam makanan kemasan, menandakan pengawasan regulasi yang lebih ketat terhadap pelabelan alergen umum dan risiko kontaminasi silang di sektor bioteknologi dan ilmu pangan.
Lihat lebih banyak
Sekitar 20j yang lalu
• Perubahan harga saham ROIV 24 jam: +22,14%. Dari 21,14 USD menjadi normalized 25,82 USD.
Saham melonjak setelah hasil uji klinis Fase 2 "transformasional" untuk brepocitinib pada sarkoidosis kutan dan pengajuan NDA untuk dermatomiositis, menutupi kerugian Q3 yang lebih besar dari perkiraan.
• Dari perspektif teknikal, ROIV berada dalam "breakout bullish kuat": pergerakan harga menembus level tertinggi 52 minggu sebelumnya di $23,91 dengan volume besar (3,6x rata-rata). Meskipun RSI (14) di 82,8 menunjukkan kondisi overbought, saham tetap dalam tren naik yang terkonfirmasi di atas semua rata-rata pergerakan utama (50-DMA di $22,22, 200-DMA di $22,30), menandakan momentum tinggi.
• Roivant Sciences melaporkan rugi bersih Q3 sebesar $265,9 juta pada 6 Februari, namun saham melonjak karena investor fokus pada data positif Fase 2 yang menunjukkan peningkatan CSAMI-A sebesar 22,3 poin untuk obat brepocitinib.
• Perusahaan secara resmi mengajukan New Drug Application (NDA) untuk brepocitinib dalam pengobatan dermatomiositis, memposisikan diri untuk potensi peluncuran komersial pada 2026.
• CEO Matt Gline menekankan "neraca yang sangat kuat" dengan kas $4,5 miliar, memberikan landasan panjang untuk pengembangan model "Vant" perusahaan.
• Eli Lilly menandatangani kolaborasi senilai $8,8 miliar dengan Innovent pada 9 Februari untuk memperluas portofolio onkologi dan metabolik di luar struktur lisensi tradisional.
• FDA menolak terapi gen Regenxbio untuk sindrom Hunter pada 9 Februari, menyoroti tantangan regulasi yang berkelanjutan bagi platform bioteknologi khusus meskipun ada pemulihan sektor secara umum.
Lihat lebih banyak
Sekitar 1H yang lalu

ROIV stock price forecast

Berdasarkan indikator teknis untuk saham ROIV, harga diperkirakan akan berfluktuasi di kisaran 26.92–35.73 USD selama seminggu ke depan. Analis pasar memprediksi bahwa harga saham ROIV kemungkinan akan berfluktuasi di kisaran 25.50–42.47 USD selama beberapa bulan ke depan.

Based on 1-year price forecasts from 73 analysts, the highest estimate is 49.37 USD, while the lowest estimate is 19.52 USD.

For more information, please see the ROIV stock price forecast Stock Price Forecast page.

Hanya dengan akun Bitget, kamu dapat trading saham dan mata uang kripto secara bersamaan.

Gabung Sekarang!

FAQ

Berapa harga saham Roivant Sciences Ltd.?

ROIV saat ini diperdagangkan pada harga 27.82 USD — harganya telah berubah sebesar 0.56% dalam 24 jam terakhir. Kamu dapat memantau kinerja harga saham Roivant Sciences Ltd. secara lebih detail pada grafik harga di bagian atas halaman ini.

Apa ticker saham dari Roivant Sciences Ltd.?

Tergantung pada exchange, ticker saham dapat bervariasi. Misalnya, di NASDAQ, Roivant Sciences Ltd. diperdagangkan dengan ticker saham ROIV.

Berapa prakiraan harga saham ROIV?

Kami telah mengumpulkan pendapat para analis mengenai harga Roivant Sciences Ltd. dimasa depan. Menurut prakiraan mereka, ROIV memiliki estimasi maksimum 278.25 USD dan estimasi minimum 55.65 USD.

Berapa kapitalisasi pasar Roivant Sciences Ltd.?

Roivant Sciences Ltd. memiliki kapitalisasi pasar sebesar 19.91B USD.

What is P/E ratio (TTM)?

The P/E ratio (TTM) stands for price-to-earnings ratio (trailing twelve months). It is a historical valuation metric calculated using a company's earnings per share (EPS) over the most recent twelve consecutive months, reflecting the company's past profitability.

The P/E ratio measures the relationship between a stock's price and a company's profitability, and is often used as a basis for judging whether a stock is "cheap" or "expensive."

P/E ratio = market price (P) ÷ earnings per share (EPS), or P/E ratio = total market capitalization ÷ net profit attributable to shareholders

The interpretation of the P/E ratio (TTM) should always be considered alongside other factors and is mainly used for valuation comparisons rather than as a standalone indicator.

  • A lower P/E ratio (TTM) means investors are paying less for each unit of earnings. This may indicate that the stock is undervalued, or that the market has limited expectations for the company's future growth, such as in mature or slow-growing industries.
  • A higher P/E ratio (TTM) means investors are paying more for each unit of earnings. This often reflects expectations of strong future earnings growth, which is common among growth or technology stocks, though it may also suggest the stock is overvalued.
  • Comparison with peers: Compare the company's P/E (TTM) with the average or median P/E of other companies in the same industry. A significantly higher P/E may require further analysis to determine whether the company's high valuation is justified by stronger growth prospects or competitive advantages.
  • Comparison with historical levels: Compare the company's current P/E (TTM) with its own historical average (such as over the past 5 or 10 years) to assess whether the current valuation is at a historical high or low.
  • Comparison with the broader market: Compare the company's P/E (TTM) with major market indices (such as the S&P 500) to see how the market is valuing the company overall.

P/E ratios can vary widely across industries, and there is no single "ideal" P/E level. A reasonable P/E range depends on the industry, the company's growth potential, and the broader macroeconomic environment. Investment decisions should not rely solely on the P/E ratio (TTM) but should be based on a comprehensive analysis that includes company quality, growth prospects, and financial health.

Can I trade stocks on Bitget?

You can trade stocks on Bitget, but mainly through stock tokens and stock perps, rather than by directly buying or selling traditional stocks.

This approach reflects Bitget's vision as a Universal Exchange (UEX), designed to connect traditional financial markets with cryptocurrency markets.

Bitget currently offers the following stock-related trading formats:

1. Stock tokens (spot)

Nature: Stock tokens are digital tokens pegged to the price of specific traditional stocks (such as TSLAUSDT and NVDAUSDT) and are traded on Bitget's spot market.

Features: When you trade stock tokens, you are buying and holding tokens rather than owning the underlying traditional stocks.

  • The price of these tokens generally follows the price movements of the stocks they are pegged to, such as Tesla or Nvidia.
  • The advantage is that you can participate in the price movements of traditional financial assets, such as U.S. stocks, using cryptocurrencies (for example, USDT), without the need for a traditional brokerage account.

2. Stock perps

Nature: Bitget also offers USDT-margined perpetual futures, commonly referred to as stock perps, based on major U.S. blue-chip stocks such as Tesla and Meta.

Characteristics: Stock perps are derivative products that allow you to take a bullish or bearish view on the future price of an underlying stock through margin trading. These products typically support leverage, such as up to 25x.

It does not involve owning the underlying stock. Instead, profits and losses are settled based on price movements of the futures.

Important note: When trading stock perps on Bitget, you are participating in derivative markets within the cryptocurrency ecosystem. This is fundamentally different from purchasing publicly traded shares through a traditional brokerage, as you do not own equity in the underlying company.

Futures trading and the use of leverage involve high risk. Please ensure you fully understand the risks before trading.

If you wish to directly hold equity in traditional stocks and enjoy shareholder rights (such as receiving dividends), you must trade through a regulated traditional securities brokerage or brokerage platform.

What are the advantages of Bitget's stock perps?

Bitget's stock perps—typically perpetual futures based on stock tokens prices—are an innovative offering that allows cryptocurrency platforms to provide exposure to traditional financial markets.

Compared to traditional stock or futures trading, they offer several unique advantages, primarily due to the platform's trading infrastructure.

Bitget's stock perps, typically USDT-denominated derivatives, offer the following key advantages:

1. Trading convenience and global accessibility

  • 24/7 trading: Traditional stock markets, such as U.S. equity markets, operate during fixed trading hours. In contrast, cryptocurrency derivatives markets are typically open 24/7. This means investors can trade anytime, capitalizing on breaking news or market fluctuations.
  • Lower entry barriers and faster onboarding: Compared with traditional brokerages, which often require extensive identity verification and lengthy account setup processes, Bitget generally offers faster account onboarding. Users can trade using cryptocurrencies such as USDT, without the need for complex fiat deposit and withdrawal procedures.
  • Global accessibility: Users can access derivatives trading linked to globally recognized stocks via the Bitget platform, subject to applicable regulations.

2. Capital efficiency and high leverage

  • High leverage options: Stock perps typically offer higher leverage than traditional stock trading (for example, up to 25x). This allows traders to control larger positions with smaller margin requirements, improving capital efficiency.
    Note: While high leverage can amplify gains, it also amplifies losses proportionally.
  • Two-way trading: Traders can easily take both long and short positions. This means traders can potentially profit from market volatility whether stock prices rise or fall, provided the market direction is correctly anticipated.

3. Trading and settlement using cryptocurrency

  • USDT margin: Stock perps on Bitget typically use USDT (or other stablecoins) as the margin and settlement currency. For users who already hold cryptocurrency, there is no need to convert assets into fiat currency, allowing them to trade directly with stablecoins.
  • Efficient fund transfers: Crypto-based transfers and settlements are typically faster than traditional fiat systems, enabling more efficient global fund allocation.

4. Integration

One-stop platform: Bitget allows users to trade spot cryptocurrencies, crypto derivatives, and stock perps on a single platform, making it easier to manage different asset types in one place.

Peringatan risiko:

While Bitget's stock perps offer several advantages, it is important to understand the associated risks.

  • High leverage risk: Leveraged trading can result in rapid loss of your entire margin.
  • No equity ownership: When trading stock perps, you do not own the underlying shares. As a result, you are not entitled to dividends or voting rights.
  • Market liquidity risk: Tokenized stock perps may have lower liquidity than their counterparts in traditional stock markets, especially outside regular trading hours.

In summary, Bitget's stock perps offer advantages such as greater trading flexibility, lower entry barriers, and higher capital efficiency.

What are the trading fees for Bitget stock perps?

Trading fees for Bitget stock perps (USDT-margined perpetual futures) mainly include transaction fees and funding rates.

Transaction fees:

Bitget offers limited-time fee promotions for stock perps (especially tokenized stock perps) from time to time to attract traders.

Standard reference rates: Under Bitget's standard futures fee structure, the taker fee is typically around 0.06%, while the maker fee is around 0.02%.

Current promotions for stock perps (important): To promote its stock perps products, Bitget is offering discounted transaction fees during Q4 2025, with taker fees as low as 0.006% and maker fees as low as 0.002%. There is also a limited-time promotion offering zero-fee trading for spot stock tokens.

Rekomendasi: Karena kegiatan promosi dapat berubah atau berakhir kapan saja, silakan kunjungi halaman resmi “ Fee overview ” atau “ Announcement Center ” Bitget untuk mendapatkan tarif terbaru dan paling akurat pada saat melakukan perdagangan.

Funding rate:

The funding rate is a key mechanism in perpetual futures (including stock perps) that helps keep the futures price closely aligned with the spot price of the underlying asset. It is not a fee charged by the platform, but a periodic payment exchanged between long and short traders.

Funding rates fluctuate dynamically and are mainly driven by market sentiment and imbalances between long and short positions. Stock perps generally experience lower volatility than cryptocurrencies, so funding rates are often relatively low during stable market conditions. However, during earnings seasons or major positive or negative news events, heavy concentration of long or short positions—such as in high-growth technology stocks like Tesla or Nvidia—can create significant imbalances, causing funding rates to spike in the short term.

Funding payments are typically settled every 8 hours. If you close your position before the funding settlement time, no funding payment will be charged or received.

Funding rates are not fixed. If you hold a position for an extended period, high positive funding rates (for long positions) or high negative funding rates (for short positions) will affect your overall holding costs or potential returns. For this reason, it is important to monitor the funding rate in real time on the trading interface.

NASDAQ/
ROIV